Stocktoria
Q/C TECHNOLOGIES, INC. QCLS
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2008-07-24
Q/C TECHNOLOGIES, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $1.6M | $1.7M | $3.9M | $3.0M |
| Gross profit | — | — | — | — | — | — | $478,747 | $127,285 | $948,580 | $1.9M |
| R&D expense | $3.5M | $3.4M | $7.9M | $9.1M | $6.7M | $2.5M | $276,788 | $1.1M | $1.3M | $1.2M |
| Operating income | -$9.8M | -$10.2M | -$17.1M | -$15.3M | -$28.8M | -$9.5M | -$3.5M | -$10.1M | -$6.6M | -$3.3M |
| Net income | -$11.6M | -$23.4M | -$4.0M | -$15.2M | -$29.9M | -$9.5M | -$3.9M | -$10.8M | -$7.4M | -$3.3M |
| EPS (diluted) | $-8.66 | $-1080.87 | $-5.33 | $-11.74 | — | — | — | — | — | — |
| Operating cash flow | -$9.1M | -$9.0M | -$13.0M | -$12.3M | -$19.5M | -$4.7M | -$3.1M | -$8.5M | -$5.1M | -$4.2M |
| Free cash flow | — | — | — | — | — | — | — | -$8.6M | -$5.1M | -$4.3M |
| Cash & equivalents | $986,996 | $173,154 | $2.7M | $749,090 | $555,967 | $148,284 | $517,444 | $181,755 | $438,432 | $72,700 |
| Inventory | — | — | — | — | — | $197,723 | $198,985 | $585,267 | $947,612 | $2.0M |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M | $676,697 | $10.9M | $7.8M | $9.3M | $5.1M |
| Total liabilities | $16.4M | $6.7M | $5.1M | $2.8M | $1.2M | $5.9M | $1.5M | $2.0M | $1.8M | $1.7M |
| Shareholders' equity | $21.8M | $9.8M | $12.4M | $14.7M | $23.6M | -$5.3M | -$2.3M | $5.8M | $7.6M | $3.4M |
Growth · year-over-year · Revenue CAGR -18.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -5.3% | -57.6% | +32.7% | +40.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.